(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual revenue growth rate of 320.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Rani Therapeutics Holdings's revenue in 2025 is $1,028,000.On average, 1 Wall Street analysts forecast RANI's revenue for 2025 to be $57,481,679, with the lowest RANI revenue forecast at $57,481,679, and the highest RANI revenue forecast at $57,481,679. On average, 2 Wall Street analysts forecast RANI's revenue for 2028 to be $1,397,379,616, with the lowest RANI revenue forecast at $814,515,391, and the highest RANI revenue forecast at $1,980,243,842.
In 2029, RANI is forecast to generate $8,889,254,249 in revenue, with the lowest revenue forecast at $4,324,346,711 and the highest revenue forecast at $13,454,161,787.